title: Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147.
abstract: Alcohol consumption is associated with a modest increased risk of colon cancer, but its relationship with colon cancer survival has not been elucidated. Using data from a phase III randomized adjuvant trial, we assessed the association of alcohol consumption with colon cancer outcomes. Patients completed a risk factor questionnaire before randomization to FOLFOX or FOLFOX + cetuximab (N = 1984). Information was collected on lifestyle factors, including smoking, physical activity and consumption of different types of alcohol. Cox models assessed the association between alcohol consumption and outcomes of disease-free survival (DFS), time-to-recurrence (TTR) and overall survival (OS), adjusting for age, sex, study arm, body mass, smoking, physical activity and performance status. No statistically significant difference in outcomes between ever and never drinkers were noted [hazard ratio (HR)DFS  = 0.86, HRTTR  = 0.87, HROS  = 0.86, p-values = 0.11-0.17]. However, when considering alcohol type, ever consumers of red wine (n = 628) had significantly better outcomes than never consumers (HRDFS  = 0.80, HRTTR  = 0.81, HROS  = 0.78, p-values = 0.01-0.02). Favorable outcomes were confirmed in patients who consumed 1-30 glasses/month of red wine (n = 601, HR = 0.80-0.83, p-values = 0.03-0.049); there was a suggestion of more favorable outcomes in patients who consumed >30 glasses/month of red wine (n = 27, HR = 0.33-0.38, p-values = 0.05-0.06). Beer and liquor consumption were not associated with outcomes. Although alcohol consumption was not associated with colon cancer outcomes overall, mild to moderate red wine consumption was suggestively associated with longer OS, DFS and TTR in stage III colon cancer patients.
authors.affiliation: Epidemiology Department, University of Washington, Seattle, WA.|Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
authors.forename: Amanda I
authors.initials: AI
authors.lastname: Phipps
authors.affiliation: Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.
authors.forename: Qian
authors.initials: Q
authors.lastname: Shi
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Limburg
authors.affiliation: Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.
authors.forename: Garth D
authors.initials: GD
authors.lastname: Nelson
authors.affiliation: Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Sargent
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
authors.forename: Frank A
authors.initials: FA
authors.lastname: Sinicrope
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
authors.forename: Emily
authors.initials: E
authors.lastname: Chan
authors.affiliation: Division of Medical Oncology, University of British Columbia, British Columbia Cancer Agency, Vancouver, BC, Canada.
authors.forename: Sharlene
authors.initials: S
authors.lastname: Gill
authors.affiliation: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
authors.forename: Richard M
authors.initials: RM
authors.lastname: Goldberg
authors.affiliation: Surgical Oncology Associates of South Texas, San Antonio, TX.
authors.forename: Morton
authors.initials: M
authors.lastname: Kahlenberg
authors.affiliation: Lehigh Valley Hospital, Allentown, PA.
authors.forename: Suresh
authors.initials: S
authors.lastname: Nair
authors.affiliation: Karmanos Cancer Institute, Wayne State University, Detroit, MI.
authors.forename: Anthony F
authors.initials: AF
authors.lastname: Shields
authors.affiliation: Epidemiology Department, University of Washington, Seattle, WA.|Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
authors.forename: Polly A
authors.initials: PA
authors.lastname: Newcomb
authors.affiliation: Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.
authors.forename: Steven R
authors.initials: SR
authors.lastname: Alberts
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000428:Alcohol Drinking; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D017326:Clinical Trials, Phase III as Topic; D003110:Colonic Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D055815:Young Adult
keywords: alcohol; colon cancer; recurrence; red wine; survival